DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Meyer T, Fox R, Ma YT. et al.
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Lancet Gastroenterol Hepatol 2017;
2 (08) 565-575
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.